Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alitair Pharmaceuticals has received a second patent from the US Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate, benzonatate polacrilex.
Subscribe to our email newsletter
The new patent contains a composition of matter claim covering the use of the company’s ion exchange formulation of benzonatate.
Claims for using benzonatate polacrilex to reduce or remove the choking hazard associated with conventional liquid formulations of benzonatate are also included in the new patent.
Alitair president and CEO William Howard said: "Benzonatate is the only FDA-approved non-narcotic prescription cough product, but its use is limited due to a significant choking hazard if a patient bites into the liquid-filled gel caps currently marketed.
"Our product is a solid oral ion exchange resin formulation and has been shown to reduce or eliminate the choking hazard associated with benzonatate.
"Through some extremely innovative work, we were able to bind benzonatate to a resin particle. This had never been done before and is a testament to the ingenuity of Dr. Russell Somma, Dr. Sheldon Kavesh, and Dr. Lyn Hughes."